Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female adults and adolescents (≥12 years and ≥40 kg)~* Chronic atopic dermatitis (according to American Academy of Dermatology Consensus Criteria) that has been present for ≥1 year before the screening visit~* Eczema Area and Severity Index (EASI) score ≥16 at the baseline visit~* Investigator Global Assessment (IGA) score ≥3 (scale of 0 to 4) at the baseline visit~* ≥10% body surface area (BSA) of atopic dermatitis involvement at the baseline visit~* History of inadequate response to treatment with topical medications; or determination that topical treatments are otherwise medically inadvisable~Exclusion Criteria:~* Prior treatment with dupilumab or tralokinumab~* Treatment with topical corticosteroids, calcineurin inhibitors or phosphodiesterase-4 inhibitors such as crisaborole within 1 week prior to the baseline visit~* Treatment with any of the following agents within 4 weeks prior to the baseline visit:~  * Immunosuppressive/immunomodulating drugs (e.g., systemic corticosteroids, cyclosporine, mycophenolate-mofetil, IFN-γ, Janus kinase inhibitors, azathioprine, methotrexate, etc.)~ * Phototherapy and photochemotherapy (PUVA) for AD~* Treatment with the following prior to the baseline visit:~  * An investigational drug within 8 weeks or within 5 half-lives (if known) of baseline, whichever is longer~ * Cell-depleting biologics, including to rituximab, within 6 months of baseline~ * Other biologics within 5 half-lives (if known) or 16 weeks of baseline, whichever is longer~* Treatment with a live (attenuated) vaccine within 12 weeks of the baseline visit or planned during the study~* Uncontrolled chronic disease that might require bursts of oral corticosteroids, e.g., co-morbid severe uncontrolled asthma~* Evidence of active acute or chronic hepatitis~* History of human immunodeficiency virus (HIV) infection or positive HIV serology~* History of malignancy, including mycosis fungoides, within 5 years before the screening visit, except completely treated in situ carcinoma of the cervix, completely treated and resolved non-metastatic squamous or basal cell carcinoma of the skin~* Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Induction Period (Baseline-Week 16):~Two subcutaneous (SC) injections of Placebo as a loading dose at Baseline and Week 2 followed by a single injection every 2 weeks (Q2W) from Week 4 until Week 14.~Maintenance Period (Week 16-Week 52):~Two placebo SC injections as loading dose on Week 16 and Week 18. One placebo SC injection Q2W until Week 50.
- Lebrikizumab 250 Q2W (Type: EXPERIMENTAL): Induction Period (Baseline-Week 16):~500 milligram (mg) Lebrikizumab (2 x 250 mg) SC injections as a loading dose at Baseline and Week 2 visits followed by a single 250 mg Lebrikizumab injection Q2W from Week 4 until Week 14.~Maintenance Period (Week 16-Week 52):~One 250 mg Lebrikizumab SC injection Q2W until Week 50.~For participants who received placebo in the Induction Period, the maintenance loading dose is:~Two 250 mg Lebrikizumab SC injections on Week 16.~Two 250 mg Lebrikizumab SC injections on Week 18.~To maintain the blind, for participants who received Lebrikizumab in the Induction Period, the maintenance loading dose is:~One 250 mg Lebrikizumab SC injection and one placebo SC injection on Week 16.~One 250 mg Lebrikizumab SC injection and one placebo SC injection on Week 18.
- Lebrikizumab 250 Q4W (Type: EXPERIMENTAL): Maintenance Period (Week 16-Week 52):~One 250 mg Lebrikizumab SC injection every 4 weeks (Q4W) on Weeks 20, 24, 28, 32, 36, 40, 44, and 48.~One placebo SC injection Q4W on Weeks 22, 26, 30, 34, 38, 42, 46, and 50.~For participants who received placebo in the Induction Period, the maintenance loading dose is:~Two 250 mg Lebrikizumab SC injections on Week 16.~Two placebo injections on Week 18.~To maintain the blind, for participants who received Lebrikizumab in the Induction Period, the maintenance loading dose is:~One 250 mg Lebrikizumab SC injection and one placebo SC injection on Week 16.~Two placebo injections on Week 18
- Escape Arm (Lebrikizumab Q2W) (Type: EXPERIMENTAL): Maintenance Period (Week 16-Week 52):~Blinded loading doses based on prior treatment assignment will be administered, followed by one 250 mg Lebrikizumab SC injection Q2W until Week 50 in an open-label fashion.~For participants who received placebo in the Induction Period, the loading dose is:~Two 250 mg Lebrikizumab SC injections on Week 16.~Two 250 mg Lebrikizumab SC injections on Week 18.~To maintain the loading dose blind, for participants who received Lebrikizumab in the Induction Period, the loading dose is:~One 250 mg Lebrikizumab SC injection and one placebo SC injection on Week 16. One 250 mg Lebrikizumab SC injection and one placebo SC injection on Week 18.~For participants who do not maintain an acceptable response during the Maintenance Period and entered the Escape Arm, the loading doses will be administrated at entry and 2 weeks after entry based on the treatment assignment prior to entering escape arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).